 Rasa Kazlauskaite
Concepts (257)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Women's Health | 14 | 2021 | 228 | 1.920 |
Why?
| | Adiposity | 8 | 2018 | 51 | 1.680 |
Why?
| | Menopause | 9 | 2021 | 121 | 1.660 |
Why?
| | Intra-Abdominal Fat | 6 | 2021 | 48 | 1.460 |
Why?
| | Obesity | 6 | 2018 | 338 | 1.270 |
Why?
| | Diabetes Mellitus, Type 2 | 6 | 2015 | 224 | 1.180 |
Why?
| | Cardiovascular Diseases | 8 | 2021 | 410 | 1.100 |
Why?
| | Thrombosis | 2 | 2014 | 67 | 0.960 |
Why?
| | Obesity, Abdominal | 4 | 2015 | 22 | 0.930 |
Why?
| | Middle Aged | 36 | 2021 | 11209 | 0.870 |
Why?
| | Adrenal Gland Diseases | 2 | 2012 | 3 | 0.850 |
Why?
| | Atrial Fibrillation | 2 | 2014 | 197 | 0.810 |
Why?
| | Female | 43 | 2021 | 18253 | 0.760 |
Why?
| | Abdominal Fat | 3 | 2021 | 12 | 0.750 |
Why?
| | Diet Therapy | 1 | 2018 | 11 | 0.730 |
Why?
| | Weight Reduction Programs | 1 | 2018 | 13 | 0.730 |
Why?
| | Atherosclerosis | 3 | 2021 | 57 | 0.700 |
Why?
| | Behavior Therapy | 1 | 2018 | 86 | 0.680 |
Why?
| | Exercise Therapy | 1 | 2018 | 116 | 0.660 |
Why?
| | Risk Factors | 20 | 2021 | 2664 | 0.650 |
Why?
| | Testosterone | 2 | 2014 | 36 | 0.650 |
Why?
| | Hydrocortisone | 3 | 2012 | 54 | 0.650 |
Why?
| | Waist-Height Ratio | 1 | 2016 | 6 | 0.640 |
Why?
| | Metabolic Diseases | 1 | 2016 | 15 | 0.630 |
Why?
| | African Americans | 7 | 2017 | 818 | 0.630 |
Why?
| | Humans | 46 | 2021 | 31481 | 0.620 |
Why?
| | United States | 15 | 2021 | 2539 | 0.590 |
Why?
| | Adult | 22 | 2021 | 9779 | 0.590 |
Why?
| | Mass Screening | 1 | 2016 | 199 | 0.550 |
Why?
| | Cognition Disorders | 2 | 2020 | 1075 | 0.510 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2014 | 54 | 0.510 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2013 | 12 | 0.500 |
Why?
| | Adrenal Cortex Function Tests | 1 | 2012 | 1 | 0.490 |
Why?
| | Hemodynamics | 1 | 2012 | 103 | 0.470 |
Why?
| | Prevalence | 4 | 2016 | 544 | 0.470 |
Why?
| | Adrenocorticotropic Hormone | 2 | 2009 | 11 | 0.460 |
Why?
| | Postmenopause | 6 | 2019 | 66 | 0.460 |
Why?
| | Liver Cirrhosis | 1 | 2012 | 60 | 0.460 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2009 | 5 | 0.450 |
Why?
| | Lipoproteins, HDL | 3 | 2014 | 32 | 0.450 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2021 | 22 | 0.440 |
Why?
| | Perimenopause | 3 | 2021 | 19 | 0.430 |
Why?
| | Longitudinal Studies | 9 | 2020 | 1452 | 0.410 |
Why?
| | Diastole | 1 | 2010 | 38 | 0.400 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 83 | 0.400 |
Why?
| | Adrenal Insufficiency | 1 | 2009 | 7 | 0.400 |
Why?
| | Vitamin D | 1 | 2010 | 24 | 0.400 |
Why?
| | Follow-Up Studies | 9 | 2020 | 2028 | 0.390 |
Why?
| | Cardiomyopathies | 1 | 2010 | 39 | 0.390 |
Why?
| | Blood Glucose | 5 | 2020 | 137 | 0.390 |
Why?
| | Pituitary Diseases | 1 | 2008 | 3 | 0.370 |
Why?
| | Hypothalamic Diseases | 1 | 2008 | 6 | 0.370 |
Why?
| | Reproducibility of Results | 4 | 2014 | 886 | 0.350 |
Why?
| | Hypertension | 4 | 2021 | 283 | 0.340 |
Why?
| | Body Mass Index | 5 | 2018 | 458 | 0.330 |
Why?
| | Prospective Studies | 6 | 2020 | 1934 | 0.330 |
Why?
| | Population Surveillance | 2 | 2020 | 127 | 0.320 |
Why?
| | Depression | 3 | 2018 | 516 | 0.310 |
Why?
| | Sensitivity and Specificity | 3 | 2014 | 580 | 0.310 |
Why?
| | Cohort Studies | 7 | 2020 | 2014 | 0.310 |
Why?
| | Exercise | 3 | 2018 | 454 | 0.300 |
Why?
| | Ketone Bodies | 1 | 2005 | 5 | 0.300 |
Why?
| | Prognosis | 3 | 2020 | 1028 | 0.290 |
Why?
| | Risk Assessment | 3 | 2020 | 806 | 0.290 |
Why?
| | ROC Curve | 3 | 2009 | 153 | 0.280 |
Why?
| | Male | 13 | 2020 | 17583 | 0.270 |
Why?
| | Incidence | 5 | 2020 | 829 | 0.270 |
Why?
| | Estradiol | 4 | 2021 | 68 | 0.260 |
Why?
| | Pregnanediol | 2 | 2021 | 6 | 0.260 |
Why?
| | Luteinizing Hormone | 2 | 2021 | 14 | 0.260 |
Why?
| | Diet | 2 | 2019 | 202 | 0.260 |
Why?
| | Pharmacoepidemiology | 2 | 2020 | 5 | 0.260 |
Why?
| | Insulin | 2 | 2011 | 116 | 0.260 |
Why?
| | Chicago | 5 | 2014 | 955 | 0.250 |
Why?
| | Life Style | 2 | 2018 | 219 | 0.250 |
Why?
| | Energy Intake | 3 | 2019 | 99 | 0.250 |
Why?
| | Atrial Appendage | 2 | 2014 | 47 | 0.240 |
Why?
| | Waist Circumference | 4 | 2016 | 34 | 0.240 |
Why?
| | Hypoglycemic Agents | 1 | 2003 | 76 | 0.240 |
Why?
| | Energy Metabolism | 2 | 2018 | 82 | 0.230 |
Why?
| | Stroke Volume | 2 | 2014 | 64 | 0.230 |
Why?
| | Menstrual Cycle | 2 | 2021 | 36 | 0.220 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2018 | 332 | 0.220 |
Why?
| | Hyperglycemia | 2 | 2020 | 49 | 0.220 |
Why?
| | Aged | 11 | 2020 | 10295 | 0.220 |
Why?
| | Progesterone | 1 | 2021 | 39 | 0.220 |
Why?
| | Cosyntropin | 2 | 2012 | 3 | 0.210 |
Why?
| | Carotid Artery Diseases | 1 | 2021 | 49 | 0.210 |
Why?
| | Insulin Resistance | 4 | 2011 | 71 | 0.200 |
Why?
| | Cholesterol, HDL | 3 | 2011 | 34 | 0.200 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2020 | 115 | 0.200 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 81 | 0.190 |
Why?
| | Seasons | 1 | 2019 | 36 | 0.190 |
Why?
| | Appetite | 1 | 2018 | 5 | 0.180 |
Why?
| | Cerebral Hemorrhage | 1 | 2020 | 141 | 0.180 |
Why?
| | Antidepressive Agents | 1 | 2019 | 108 | 0.180 |
Why?
| | Fractures, Bone | 1 | 2019 | 62 | 0.180 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 91 | 0.180 |
Why?
| | Weight Gain | 1 | 2018 | 70 | 0.170 |
Why?
| | Body Weight | 1 | 2018 | 167 | 0.170 |
Why?
| | Chronic Disease | 1 | 2020 | 544 | 0.170 |
Why?
| | Weight Loss | 1 | 2018 | 114 | 0.170 |
Why?
| | Hormones | 1 | 2017 | 19 | 0.170 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 462 | 0.160 |
Why?
| | Beverages | 1 | 2016 | 13 | 0.160 |
Why?
| | Depressive Disorder | 1 | 2018 | 212 | 0.160 |
Why?
| | Social Support | 1 | 2018 | 224 | 0.160 |
Why?
| | Time Factors | 4 | 2020 | 1902 | 0.160 |
Why?
| | Climacteric | 1 | 2015 | 10 | 0.150 |
Why?
| | Cross-Sectional Studies | 3 | 2009 | 986 | 0.150 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 637 | 0.150 |
Why?
| | Retrospective Studies | 5 | 2014 | 3591 | 0.150 |
Why?
| | False Positive Reactions | 1 | 2015 | 40 | 0.150 |
Why?
| | Estrogens | 1 | 2015 | 36 | 0.150 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 23 | 0.150 |
Why?
| | Immunoassay | 1 | 2015 | 45 | 0.140 |
Why?
| | Child | 3 | 2009 | 1572 | 0.140 |
Why?
| | Carbonated Beverages | 1 | 2014 | 2 | 0.140 |
Why?
| | Sweetening Agents | 1 | 2014 | 8 | 0.140 |
Why?
| | Waist-Hip Ratio | 1 | 2014 | 17 | 0.140 |
Why?
| | Research Report | 1 | 2014 | 11 | 0.140 |
Why?
| | Algorithms | 2 | 2009 | 412 | 0.140 |
Why?
| | Birth Weight | 1 | 2015 | 45 | 0.140 |
Why?
| | Meals | 1 | 2014 | 15 | 0.140 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2015 | 36 | 0.140 |
Why?
| | Illinois | 2 | 2013 | 266 | 0.130 |
Why?
| | Age Factors | 3 | 2020 | 943 | 0.130 |
Why?
| | Hyperandrogenism | 1 | 2014 | 2 | 0.130 |
Why?
| | Oligomenorrhea | 1 | 2014 | 2 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 3 | 2014 | 891 | 0.130 |
Why?
| | Self Report | 3 | 2020 | 225 | 0.130 |
Why?
| | Personal Satisfaction | 1 | 2014 | 52 | 0.130 |
Why?
| | Echocardiography, Transesophageal | 1 | 2014 | 52 | 0.130 |
Why?
| | Body Image | 1 | 2014 | 37 | 0.130 |
Why?
| | Employment | 1 | 2013 | 39 | 0.130 |
Why?
| | Heart Valve Diseases | 1 | 2013 | 32 | 0.120 |
Why?
| | Body Fat Distribution | 1 | 2012 | 12 | 0.120 |
Why?
| | Blood Pressure | 4 | 2019 | 260 | 0.120 |
Why?
| | Logistic Models | 3 | 2019 | 479 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 230 | 0.110 |
Why?
| | Motor Activity | 2 | 2018 | 397 | 0.110 |
Why?
| | Ultrasonography | 1 | 2013 | 210 | 0.110 |
Why?
| | Up-Regulation | 1 | 2012 | 220 | 0.110 |
Why?
| | Subcutaneous Fat, Abdominal | 1 | 2011 | 2 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 390 | 0.110 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 1300 | 0.100 |
Why?
| | Calcifediol | 1 | 2010 | 2 | 0.100 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2010 | 3 | 0.100 |
Why?
| | Metyrapone | 1 | 2009 | 1 | 0.100 |
Why?
| | Glucose Tolerance Test | 1 | 2009 | 11 | 0.100 |
Why?
| | Socioeconomic Factors | 3 | 2020 | 362 | 0.100 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2010 | 49 | 0.100 |
Why?
| | Particle Size | 1 | 2010 | 71 | 0.100 |
Why?
| | Pericardium | 1 | 2010 | 27 | 0.100 |
Why?
| | Reference Standards | 1 | 2009 | 38 | 0.100 |
Why?
| | Breast Neoplasms | 2 | 2015 | 442 | 0.100 |
Why?
| | Antimetabolites | 1 | 2009 | 15 | 0.100 |
Why?
| | Infant | 2 | 2009 | 642 | 0.100 |
Why?
| | Alcohol Drinking | 1 | 2010 | 86 | 0.100 |
Why?
| | Follicle Stimulating Hormone | 2 | 2021 | 28 | 0.100 |
Why?
| | Child, Preschool | 2 | 2009 | 786 | 0.100 |
Why?
| | Hospitals, Public | 1 | 2009 | 31 | 0.100 |
Why?
| | Regression Analysis | 1 | 2010 | 319 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2018 | 5234 | 0.090 |
Why?
| | Health Behavior | 1 | 2010 | 177 | 0.090 |
Why?
| | Fasting | 1 | 2008 | 26 | 0.090 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 2008 | 29 | 0.090 |
Why?
| | Urban Population | 1 | 2009 | 161 | 0.090 |
Why?
| | Glucocorticoids | 1 | 2008 | 77 | 0.090 |
Why?
| | Hypercalcemia | 1 | 2007 | 12 | 0.080 |
Why?
| | Burns | 1 | 2007 | 26 | 0.080 |
Why?
| | Severity of Illness Index | 1 | 2012 | 1240 | 0.080 |
Why?
| | Carotid Arteries | 2 | 2021 | 57 | 0.080 |
Why?
| | Linear Models | 2 | 2018 | 276 | 0.080 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 150 | 0.070 |
Why?
| | Patient Education as Topic | 1 | 2007 | 192 | 0.070 |
Why?
| | Adolescent | 2 | 2009 | 2667 | 0.070 |
Why?
| | Lamin Type A | 1 | 2004 | 2 | 0.070 |
Why?
| | Intensive Care Units | 1 | 2007 | 316 | 0.070 |
Why?
| | Lipodystrophy | 1 | 2004 | 2 | 0.070 |
Why?
| | Acyltransferases | 1 | 2004 | 3 | 0.070 |
Why?
| | GTP-Binding Protein gamma Subunits | 1 | 2004 | 3 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 230 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 87 | 0.070 |
Why?
| | Gluconeogenesis | 1 | 2003 | 4 | 0.060 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2003 | 11 | 0.060 |
Why?
| | Hyperlipidemias | 1 | 2003 | 29 | 0.060 |
Why?
| | Odds Ratio | 2 | 2015 | 327 | 0.060 |
Why?
| | Fatty Acids | 1 | 2003 | 45 | 0.060 |
Why?
| | Triglycerides | 2 | 2014 | 50 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2014 | 386 | 0.060 |
Why?
| | Young Adult | 1 | 2009 | 2277 | 0.060 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 4 | 0.060 |
Why?
| | Ankle Brachial Index | 1 | 2021 | 7 | 0.060 |
Why?
| | Vasomotor System | 1 | 2021 | 5 | 0.050 |
Why?
| | Liver | 1 | 2003 | 214 | 0.050 |
Why?
| | Patient Selection | 1 | 2003 | 264 | 0.050 |
Why?
| | Affect | 1 | 2021 | 72 | 0.050 |
Why?
| | Cognition | 1 | 2009 | 1206 | 0.050 |
Why?
| | Morbidity | 1 | 2020 | 71 | 0.050 |
Why?
| | Hypertriglyceridemia | 2 | 2014 | 25 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2003 | 389 | 0.050 |
Why?
| | Disease Progression | 1 | 2003 | 861 | 0.050 |
Why?
| | Diet Surveys | 1 | 2019 | 26 | 0.050 |
Why?
| | Propensity Score | 1 | 2019 | 54 | 0.050 |
Why?
| | Osteoporosis | 1 | 2019 | 74 | 0.040 |
Why?
| | Genetic Testing | 1 | 2018 | 73 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2018 | 364 | 0.040 |
Why?
| | Estrone | 1 | 2017 | 6 | 0.040 |
Why?
| | Accidental Falls | 1 | 2019 | 118 | 0.040 |
Why?
| | Corpus Luteum | 1 | 2017 | 6 | 0.040 |
Why?
| | Premenopause | 1 | 2017 | 22 | 0.040 |
Why?
| | Hospitalization | 1 | 2020 | 359 | 0.040 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 315 | 0.040 |
Why?
| | Genotype | 1 | 2018 | 423 | 0.040 |
Why?
| | Sleep | 1 | 2020 | 357 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2015 | 21 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2015 | 22 | 0.040 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 60 | 0.040 |
Why?
| | E-Selectin | 1 | 2015 | 3 | 0.040 |
Why?
| | Androgens | 1 | 2014 | 8 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2015 | 390 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2015 | 687 | 0.030 |
Why?
| | Myocardial Infarction | 1 | 2014 | 187 | 0.030 |
Why?
| | Tunica Intima | 1 | 2011 | 33 | 0.030 |
Why?
| | Nutrition Policy | 1 | 2010 | 12 | 0.030 |
Why?
| | Fruit | 1 | 2010 | 20 | 0.030 |
Why?
| | France | 1 | 2010 | 39 | 0.030 |
Why?
| | Vegetables | 1 | 2010 | 22 | 0.030 |
Why?
| | Dietary Fats | 1 | 2010 | 40 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 73 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2010 | 40 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2009 | 15 | 0.020 |
Why?
| | Biological Availability | 1 | 2009 | 26 | 0.020 |
Why?
| | Stroke | 1 | 2014 | 367 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2010 | 378 | 0.020 |
Why?
| | Aging | 1 | 2018 | 1614 | 0.020 |
Why?
| | Albumins | 1 | 2007 | 36 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2007 | 46 | 0.020 |
Why?
| | Knowledge | 1 | 2007 | 20 | 0.020 |
Why?
| | Lipids | 1 | 2007 | 56 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2015 | 3910 | 0.020 |
Why?
| | Length of Stay | 1 | 2007 | 377 | 0.020 |
Why?
| | 1-Acylglycerol-3-Phosphate O-Acyltransferase | 1 | 2004 | 1 | 0.020 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2004 | 13 | 0.020 |
Why?
| | Consanguinity | 1 | 2004 | 4 | 0.020 |
Why?
| | RNA Splice Sites | 1 | 2004 | 3 | 0.020 |
Why?
| | Frameshift Mutation | 1 | 2004 | 6 | 0.020 |
Why?
| | Hyperinsulinism | 1 | 2004 | 5 | 0.020 |
Why?
| | Pennsylvania | 1 | 2004 | 15 | 0.020 |
Why?
| | Linkage Disequilibrium | 1 | 2004 | 43 | 0.020 |
Why?
| | Exons | 1 | 2004 | 46 | 0.020 |
Why?
| | Homozygote | 1 | 2004 | 28 | 0.020 |
Why?
| | Haplotypes | 1 | 2004 | 63 | 0.020 |
Why?
| | Alleles | 1 | 2004 | 221 | 0.020 |
Why?
| | Calcium | 1 | 2007 | 519 | 0.020 |
Why?
| | Phenotype | 1 | 2004 | 379 | 0.020 |
Why?
|
|
Kazlauskaite's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|